Company news
Bioage Labs, Inc. (NASDAQ:BIOA) news
Every Bioage Labs, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular...
September 8, 2026
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Redu...
July 14, 2026
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in ...
June 16, 2026
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
May 8, 2026
BioAge Labs : R&D Day Presentation
May 7, 2026
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
May 4, 2026
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
April 21, 2026
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
April 13, 2026
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
March 24, 2026
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
February 9, 2026
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
January 21, 2026
BioAge Announces Proposed Public Offering
January 20, 2026
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Tria...
January 20, 2026
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential f...
January 12, 2026
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
December 4, 2025
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
November 7, 2025
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 6, 2025
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
September 15, 2025
BioAge Labs to Present at Upcoming Investor Conferences
August 20, 2025
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 15, 2025
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) ...
June 21, 2025
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
June 17, 2025
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
June 3, 2025
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candida...
May 29, 2025
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
May 6, 2025
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
March 20, 2025
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
February 20, 2025
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
January 28, 2025
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases an...
December 18, 2024
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Trea...
December 6, 2024
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
December 5, 2024
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 7, 2024
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
November 4, 2024
BioAge Labs to Present at Jefferies London Healthcare Conference
October 24, 2024
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing...
October 1, 2024
BioAge Labs Announces Pricing of Upsized Initial Public Offering
September 25, 2024